Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression

Area of Science:

• Hematology
• Molecular Biology
• Oncology

Background:

• B-cell chronic lymphocytic leukemia (B-CLL) is the most common leukemia in Western countries.
• B-CLL presents as aggressive or indolent forms, distinguished by ZAP-70 expression and IgH V(H) mutation status.
• MicroRNAs (miRNAs) are implicated in various cancers, including leukemia.

Purpose of the Study:

• To investigate the role of miR-29 in the pathogenesis of B-cell chronic lymphocytic leukemia (B-CLL).
• To determine if miR-29 dysregulation contributes to the development of indolent B-CLL.

Main Methods:

• Quantitative analysis of miR-29a expression in human B-CLL patient samples and normal B cells.
• Generation of Emu-miR-29 transgenic mice overexpressing miR-29 in B cells.
• Flow cytometric analysis of spleen cell populations in transgenic mice.
• Long-term monitoring of transgenic mice for disease development and survival.

Main Results:

• miR-29a was found to be upregulated in indolent B-CLL compared to aggressive B-CLL and normal B cells.
• Emu-miR-29 transgenic mice exhibited a marked expansion of CD5(+) B cells in their spleens, a characteristic of B-CLL.
• Transgenic mice developed significantly enlarged spleens and a near-complete CD5(+) B-cell population by 2 years of age.
• 20% of the transgenic mice developed frank leukemia and died from the disease by 24-26 months of age.

Conclusions:

• Dysregulation of miR-29 can contribute to the pathogenesis of indolent B-cell chronic lymphocytic leukemia.
• miR-29 may play a crucial role in the development and progression of B-CLL.
• These findings highlight miR-29 as a potential therapeutic target in B-CLL.